These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19057979)

  • 41. Long-term clinical and pathological effects of cyclosporin in children with nephrosis.
    Seikaly MG; Prashner H; Nolde-Hurlbert B; Browne R
    Pediatr Nephrol; 2000 Mar; 14(3):214-7. PubMed ID: 10752760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome.
    Griveas I; Visvardis G; Papadopoulou D; Nakopolou L; Karanikas E; Gogos K; Stavianoudakis G
    Artif Organs; 2010 Mar; 34(3):234-7. PubMed ID: 20447050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra.
    Terrill CJ; Lill J; Somerville KT; Sherbotie JR
    J Ren Nutr; 2003 Jan; 13(1):26-30. PubMed ID: 12563620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy.
    Molpeceres J; Chacón M; Guzmán M; Berges L; del Rosario Aberturas M
    Int J Pharm; 1999 Sep; 187(1):101-13. PubMed ID: 10502617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral cyclosporine preparations immediately following renal transplantation.
    Katz SM; Amante A; Schoenberg L; Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2164. PubMed ID: 8769188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients.
    Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T
    Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics.
    Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM
    J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Testing switchability of a new microemulsion formulation of cyclosporine.
    Talaulikar GS; Srishyla MV; Job V; Selvakumar R; Thomas PP
    Transplant Proc; 2003 Dec; 35(8):2899-901. PubMed ID: 14697932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults.
    Fujiwara A; Hirawa N; Kobayashi Y; Yatsu K; Katsumata M; Ehara Y; Okuyama Y; Yutoh J; Kaneda T; Fujita M; Yamamoto Y; Saka S; Toya Y; Yasuda G; Umemura S
    Clin Exp Nephrol; 2015 Apr; 19(2):240-6. PubMed ID: 24771147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased cyclosporine exposure during the remission of nephrotic syndrome.
    Medeiros M; Pérez-Urizar J; Mejía-Gaviria N; Ramírez-López E; Castañeda-Hernández G; Muñoz R
    Pediatr Nephrol; 2007 Jan; 22(1):84-90. PubMed ID: 17053886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?
    Ku YM; Min DI; Flanigan M
    J Clin Pharmacol; 1998 Oct; 38(10):959-65. PubMed ID: 9807978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients.
    Baraldo M; Pea F; Poz D; Furlanut M
    Pharmacol Res; 2001 Jun; 43(6):547-51. PubMed ID: 11419964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
    Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L
    Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nomogram for predicting optimal dosage of cyclosporine in renal transplant patients: taking physiological factors into consideration for regimen during immunosuppressive therapy.
    Shibata N; Hoshino N; Minouchi T; Yamaji A
    Biol Pharm Bull; 1995 Oct; 18(10):1423-9. PubMed ID: 8593449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.
    Hirunpanich V; Sato H
    Eur J Pharm Biopharm; 2009 Oct; 73(2):247-52. PubMed ID: 19560537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels].
    Takeuchi A; Shirai S; Horiuchi K; Takahashi I; Matsushima M; Hirotani M; Kano T; Yabe I; Matumoto A; Sasaki H
    Rinsho Shinkeigaku; 2012; 52(3):172-7. PubMed ID: 22453042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal cyclosporine therapy--an Indian experience.
    Raj DS; Somiah S; Mani K
    J Assoc Physicians India; 1996 Jan; 44(1):34-6. PubMed ID: 8773092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis.
    Navazo L; Salata H; Morales S; Dorta MC; Pérez F; de las Casas D; Avilés J
    Scand J Gastroenterol; 2001 Jun; 36(6):610-4. PubMed ID: 11424319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients.
    Marchesoni A; Fantini F; Battafarano N; Zeni S; Ruiu G; Padula A; Taglione E; Pasero G; Leoni L
    Rheumatol Int; 1998; 17(5):197-202. PubMed ID: 9542781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.